To compare the efficacy, relapse, and adverse effects between intralesional injection and mouth rinse of triamcinolone acetonide (TA) in patients with oral lichen planus (OLP).
Study Design
A randomized controlled study.
Setting
College medical center.
Subjects and Methods
Forty consecutive patients, who had been diagnosed with OLP, were recruited. Participants were randomly divided into 2 groups using intralesional injection or mouth rinse of TA. The severity of pain and burning sensation on a 10-cm visual analog scale (VAS) and the Oral Health Impact Profile–14 (OHIP-14) were assessed at weeks 0, 1, 2, 3, 4, and 6. The signs of OLP were quantified using a special scoring system for OLP. The rate of relapse and the adverse effects were compared between both groups.
Results
The VAS scores for pain and burning mouth sensation and objective scoring for OLP were significantly improved at 1, 2, 3, 4, and 6 weeks in both groups. The changes in the VAS for burning mouth sensation, OHIP-14, and objective scoring for OLP were similar between both groups. The change in the VAS for pain from baseline to week 1 in the intralesional injection group was significantly higher than in the mouth rinse group. The rate of adverse effects was significantly higher in the mouth rinse group than in the intralesional injection group (44.4% vs 5.0%).
Conclusion
The efficacies of both treatments were similar. The rate of adverse effects was significantly lower for intralesional injection of TA than mouth rinse of TA.
LodiGScullyCCarrozzoMGriffithsMSugermanPBThongprasomK. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etiopathogenesis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:40-51.
2.
DissemondJ. Oral lichen planus: an overview. J Dermatolog Treat. 2004;15:136-140.
3.
ZegarelliD. Multimodality steroid therapy of erosive and ulcerative oral lichen planus. J Oral Med. 1983;38:127.
4.
StoppoloniGPriscoFSantinelliRSicuranzaGGiordanoC. Potential hazards of topical steroid therapy. Am J Dis Child. 1983;137:1130-1131.
5.
PasseronTLacourJPFontasEOrtonneJP. Treatment of oral erosive lichen planus with 1% pimecrolimus cream: a double-blind, randomized, prospective trial with measurement of pimecrolimus levels in the blood. Arch Dermatol. 2007;143:472.
6.
LodiGScullyCCarrozzoMGriffithsMSugermanPBThongprasomK. Current controversies in oral lichen planus: report of an international consensus meeting. Part 2. Clinical management and malignant transformation. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2005;100:164-178.
7.
ScottJHuskissonE. Graphic representation of pain. Pain. 1976;2:175-184.
8.
SladeGD. Derivation and validation of a short-form oral health impact profile. Community Dent Oral Epidemiol. 1997;25:284-290.
9.
SladeGDNuttallNSandersAESteeleJGAllenPFLahtiS. Impacts of oral disorders in the United Kingdom and Australia. Br Dent J. 2005;198:489-493.
10.
EscudierMAhmedNShirlawP. A scoring system for mucosal disease severity with special reference to oral lichen planus. Br J Dermatol. 2007;157:765-770.
KawamuraENakamuraSSasakiM. Accumulation of oligoclonal T cells in the infiltrating lymphocytes in oral lichen planus. J Oral Pathol Med. 2003;32:282-289.
KumarSSinghRJReedAMLteifAN. Cushing’s syndrome after intra-articular and intradermal administration of triamcinolone acetonide in three pediatric patients. Pediatrics. 2004;113:1820-1824.
17.
JealWFauldsD. Triamcinolone acetonide: a review of its pharmacological properties and therapeutic efficacy in the management of allergic rhinitis. Drugs. 1997;53:257.
18.
KhannaJAndradeN. Oral submucous fibrosis: a new concept in surgical management: report of 100 cases. Int J Oral Maxillofac Surg. 1995;24:433-439.
19.
LaiDChenHLinLHuangYLTsaiCC. Clinical evaluation of different treatment methods for oral submucous fibrosis: a 10-year experience with 150 cases. J Oral Pathol Med. 1995;24:402-406.
20.
KermerCMillesiWWatzkeI. Local injection of corticosteroids for central giant cell granuloma: a case report. Int J Oral Maxillofac Surg. 1994;23:366-368.
21.
HaddadIK. Temporomandibular joint osteoarthrosis. Saudi Med J. 2000;21:675-679.
22.
RajeevanNSoumithranC. Intralesional corticosteroid injection for central giant cell granuloma: a case report. Int J Oral Maxillofac Surg. 1998;27:303-304.
23.
KurtzMMesaMAlbertoP. Treatment of a central giant cell lesion of the mandible with intralesional glucocorticosteroids. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91:636-637.
24.
XiaJLiCHongYYangLHuangYChengB. Short-term clinical evaluation of intralesional triamcinolone acetonide injection for ulcerative oral lichen planus. J Oral Pathol Med. 2006;35:327-331.
25.
XiongCLiQLinM. The efficacy of topical intralesional BCG-PSN injection in the treatment of erosive oral lichen planus: a randomized controlled trial. J Oral Pathol Med. 2009;38:551-558.
26.
FarhiDDupinN. Pathophysiology, etiologic factors, and clinical management of oral lichen planus, part I: facts and controversies. Clin Dermatol. 2010;28:100-108.
27.
UngphaiboonSNittayanantaWVuddhakulV. Formulation and efficacy of triamcinolone acetonide mouthwash for treating oral lichen planus. Am J Health Syst Pharm. 2005;62:485-491.
28.
RhodusNChengBBowlesWMyersSMillerLOndreyF. Proinflammatory cytokine levels in saliva before and after treatment of (erosive) oral lichen planus with dexamethasone. Oral Dis. 2006;12:112-116.
29.
HegartyAMcGrathCHodgsonTAPorterSR. Patient-centred outcome measures in oral medicine: are they valid and reliable?Int J Oral Maxillofac Surg. 2002;31:670-674.
30.
González-GarcíaADiniz-FreitasMGándara-VilaP. Triamcinolone acetonide mouth rinses for treatment of erosive oral lichen planus: efficacy and risk of fungal over-infection. Oral Dis. 2006;12:559-565.
31.
RödströmPHakebergMJontellMNordinP. Erosive oral lichen planus treated with clobetasol propionate and triamcinolone acetonide in Orabase: a double-blind clinical trial. J Dermatolog Treat. 1994;5:7-10.
32.
HegartyAMHodgsonTALewseyJDPorterSR. Fluticasone propionate spray and betamethasone sodium phosphate mouthrinse: a randomized crossover study for the treatment of symptomatic oral lichen planus. J Am Acad Dermatol. 2002;47:271-279.
33.
GhabanchiJNajafiRBHaghnegahdarS. Treatment of oral inflammatory diseases with a new mucoadhesive prednisolone tablet versus triamcinolone acetonide paste. Iran Red Crescent Med J. 2009;11:155-159.
34.
CarboneMArduinoPCarrozzoM. Topical clobetasol in the treatment of atrophic-erosive oral lichen planus: a randomized controlled trial to compare two preparations with different concentrations. J Oral Pathol Med. 2009;38:227-233.
35.
CampisiGGiandaliaGDe CaroVDi LibertoCAricòPGiannolaLI. A new delivery system of clobetasol-17-propionate (lipid-loaded microspheres 0.025%) compared with a conventional formulation (lipophilic ointment in a hydrophilic phase 0.025%) in topical treatment of atrophic/erosive oral lichen planus: a phase IV, randomized, observer-blinded, parallel group clinical trial. Br J Dermatol. 2004;150:984-990.
GilbertsonEOSpellmanMCPiacquadioDJMulfordMI. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations. J Am Acad Dermatol. 1998;38:318-321.
38.
ThongprasomKLuangjarmekornLSereratTTaweesapW. Relative efficacy of fluocinolone acetonide compared with triamcinolone acetonide in treatment of oral lichen planus. J Oral Pathol Med. 1992;21:456-458.
39.
Lozada-NurFMirandaCMaliksiR. Double-blind clinical trial of 0.05% clobetasol proprionate ointment in orabase and 0.05% fluocinonide ointment in orabase in the treatment of patients with oral vesiculoerosive diseases. Oral Surg Oral Med Oral Pathol. 1994;77:598-604.
40.
Gonzalez-MolesMAMoralesPRodriguez-ArchillaAIsabelIRGonzalez-MolesS. Treatment of severe chronic oral erosive lesions with clobetasol propionate in aqueous solution. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2002;93:264-270.
41.
CribierBFrancesCChosidowO. Treatment of lichen planus: an evidence-based medicine analysis of efficacy. Arch Dermatol. 1998;134:1521.
42.
CawsonR. Treatment of oral lichen planus with betamethasone. BMJ. 1968;1:86-89.
43.
LockerDJokovicAClarkeM. Assessing the responsiveness of measures of oral health-related quality of life. Community Dent Oral Epidemiol. 2004;32:10-18.
